Protara Therapeutics, Inc. (TARA)

2.9250 -0.1250 (-4.10%) At close: 04:00PM EDT

Protara Therapeutics, Inc.

345 Park Avenue South
3rd Floor
New York, NY 10010
United States
646 844 0337
https://www.protaratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jesse Shefferman	Co-Founder, CEO, President & Director	1.11M	N/A	1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.	Co-Founder, Senior VP & Chief Scientific Operations Officer	743.68k	N/A	1981
Dr. Jathin Bandari M.D.	Executive Officer	687.86k	N/A	1988
Mr. Patrick Fabbio M.B.A.	Chief Financial Officer	N/A	N/A	1968
Ms. Hannah Fry	VP, Principal Accounting Officer & Controller	N/A	N/A	1991
Ms. Justine O'Malley	Senior Vice President of Investor Relations & Corporate Affairs	N/A	N/A	N/A
Ms. Mary J. Grendell	General Counsel & Corporate Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Corporate governance

Protara Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.